Keqian Biotech (688526.SH): A total cost of 24.37 million yuan to buy back 0.3177% of the shares
Gelonghui, April 1 | Keqian Biotech (688526.SH) announced that as of March 31, 2024, the company had repurchased 1,481,214 shares of the company's shares through centralized bidding transactions, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24,372,261.54 (excluding transaction fees such as stamp duty and transaction fees).
Keqian Biology (688526.SH): A total of 1.4812 million shares have been repurchased
Gelonghui, March 1, 丨 Keqian Biotech (688526.SH) announced that as of February 29, 2024, the company had repurchased a total of 1.4812 million shares through the Shanghai Stock Exchange trading system, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24.3723 million (excluding transaction fees such as stamp duty and transaction fees).
Keqian Biotech (688526.SH): 0.11% share repurchase for the first time
Gelonghui, Feb. 27丨Keqian Biotech (688526.SH) announced that on February 27, 2024, the company repurchased 499,530 shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.11% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.62 yuan/share, the lowest price was 16.39 yuan/share, and the total amount of capital paid was RMB 8,242,245.00.
Keqian Biotech (688526.SH) performance report: 2023 net profit of 418 million yuan increased 2.17% year over year
Gelonghui, Feb. 26: Keqian Biotech (688526.SH) announced the 2023 Annual Results Report. In 2023, the company achieved operating income of 1,066 billion yuan, an increase of 6.45% over the previous year; realized net profit attributable to owners of the parent company of 418 million yuan, an increase of 2.17% over the previous year.
Keqian Biotech (688526.SH): Plans to spend 30 million yuan to 50 million yuan to buy back shares
On February 21, Gelonghui Biotech (688526.SH) announced that the company plans to buy back some of the company's issued RMB common shares (A shares) through centralized bidding transactions, all or part of them to implement employee stock ownership plans or equity incentives. The total capital of this repurchase is not less than RMB 30 million (inclusive) and not more than RMB 50 million (inclusive); the repurchase price is not more than RMB 20 per share (inclusive).
Keqian Biology (688526.SH): Intends to sign a patent transfer contract with Huazhong Agricultural University
Gelonghui (688526.SH) announced on November 28, Keqian Biology () announced that after competitive negotiations with Huazhong Agricultural University, Huazhong Agricultural University has decided to transfer the patent for “a mutated strain of the swine epidemic diarrhea virus that does not depend on pancreatin and its construction and application” to the company, and plans to sign a patent transfer contract for the above patent. The company will have to pay 2 million yuan to Huazhong Agricultural University for the above patent transfer.
Keqian Biology (688526.SH): Net profit of 357 million yuan for the first three quarters increased 26.11% year-on-year
Glonghui, Oct. 26丨Keqian Biotech (688526.SH) announced its third quarter report. Revenue was 827 million yuan, up 20.53% year on year, net profit was 357 million yuan, up 26.11% year on year, after deducting non-net profit of 340 million yuan, up 26.72% year on year, and basic earnings per share were 0.77 yuan.
Pre-clinical biology (688526.SH): Feline triple vaccine passed emergency evaluation by the Ministry of Agriculture and Rural Affairs
Keqian Biology (688526.SH) issued a notice. According to the “Regulations on the Administration of Veterinary Drugs”, “Veterinary Drug Registration Measures”, etc...
Five shareholders of Keqian Biotech (688526.SH) promised not to reduce their holdings of the company within 6 months
Keqian Biology (688526.SH) announced that the company recently received Chen Huanchunxian, a shareholder holding 5% or more of the shares...
The original co-actor agreement of Keqian Biotech (688526.SH) expired and terminated, some shareholders renewed the co-actor agreement and changed the actual controller
Keqian Biology (688526.SH) announced that the company's original co-actors Chen Huanchun, Jin Meilin, He Qigai, Wu Bin,...
Keqian Biotech (688526.SH): 341 million restricted shares will be listed and distributed from September 22, accounting for 73.18% of the total share capital
Keqian Biotech (688526.SH) announced that the restricted shares listed and in circulation this time are the company's initial public offering of restricted shares,...
Keqian Biology (688526.SH): The main product is pig vaccine, and about 95% of revenue comes from the sale of pig vaccine
Gelonghui, September 11: On the investor interactive platform, Keqian Biology (688526.SH) said that the company's main product is pig vaccine, and about 95% of revenue comes from pig vaccine sales; in terms of poultry vaccine, the company has also completed product layout and continues to increase product development and sales work. Research and development of many new products is progressing smoothly. Chicken Xincheng disease, avian influenza (H9 subtype), infectious bursil disease, and avian adenovirus disease (group I, type 4) quadruple inactivated vaccine (LASOTA+HB01 strain R+2+Fiber2) according to requirements Completed the relevant Tests and material additions, once again
Keqian Biology (688526.SH) Announces First-Half Year Results and Net Profit of 239 million yuan, up 50.31% year-on-year
Keqian Biology (688526.SH) disclosed the 2023 semi-annual report. The company achieved operating income of 5 during the reporting period...
Keqian Biotech (688526.SH): Elected Chen Mulin as Chairman
On July 5, GLONGHUI | Keqian Biotech (688526.SH) announced that the company's board of directors elected Ms. Chen Mulin as the chairman of the 3rd board of directors of the company and Mr. Zhong Ming as the vice chairman of the 3rd board of directors of the company. The term of office starts from the date this board resolution is passed until the end of the term of the 3rd board of directors.
Glonhui Announces Selected | Weichai Power's semi-annual non-net profit is expected to increase by 105% to 140%; BYD's sales volume of 253,000 new energy vehicles in June increased 88.79% year-on-year
The heavy truck industry has clearly recovered. The net profit of Sinotruk (000951.SZ) is expected to increase by 45%-65% for the half year; export of offshore products achieved batch delivery, and Daikin Heavy Industries (002487.SZ)'s net profit for the first half year increased by 45%-60%
Keqian Biotech (688526.SH): The Shanghai Stock Exchange decided to stop reviewing the company's fixed increase
On June 30, 2023, GLONGHUB (688526.SH) announced that on June 30, 2023, the company received the “Decision on Terminating the Review of the Issuance of Shares by Wuhan Keqian Biology Co., Ltd.” (Shanghai Securities Review (Refinancing) [2023] No. 161). The Shanghai Stock Exchange decided to terminate the review of the company's issuance of shares to specific targets in accordance with Article 19 of the “Shanghai Stock Exchange Listed Company Securities Issuance and Listing Review Rules” and section 63 (2) of the “Shanghai Stock Exchange Stock Exchange Stock Issuance Review Rules”.
Pre-science biology: the proposed cooperative R & D agreement with Huazhong Agricultural University will help to increase the company's product reserve.
Pre-Science Biology (688526) announced that through competitive negotiations with Huazhong Agricultural University, the company has obtained the cooperative research and development of three projects, including recombinant canine parvovirus VP2 live canine distemper virus vaccine and rabies inactivated vaccine (SAD-dOG strain). Now it intends to sign a joint development agreement with Huazhong Agricultural University, and the company needs to pay a total of 3.4 million yuan to Huazhong Agricultural University for the above three R & D projects. The technical achievements and intellectual property rights produced by the cooperative R & D project are jointly owned by the company and Huazhong Agricultural University. Through cooperative research and development, we can increase the company's product reserve and enhance the company's market competitiveness.
Dongxing Securities: give pre-science biological buy rating
2021-10-29 Dongxing Securities Co., Ltd. Cheng Shiyue, Meng Lin conducted research on pre-science biology and issued a research report "Q3 performance is not as expected, R & D advantage continues to strengthen". This report gives a buy rating to pre-science biology, and the current stock price is 25.50 yuan. Pre-science biology (688526) event: the company announced its three-quarter report in 2021 that the company achieved a total operating income of 776 million yuan in the first three quarters, an increase of 28.37% over the same period last year, a net profit of 386 million yuan, an increase of 20.69% over the same period last year, and a net cash inflow of 474 million yuan from operating activities, an increase of 32% over the same period last year.
西南证券:给予科前生物买入评级
2021-10-28西南证券股份有限公司徐卿对科前生物进行研究并发布了研究报告《养殖盈利能力或迎修复,非强免龙头长期向好》,本报告对科前生物给出买入评级,当前股价为25.07元。 科前生物(688526) 业绩总结:公司2021年前三季度实现营业收入7.8亿元,同比增长28.4%,实现归母净利润3.9亿元,同比增长20.7%。单三季度实现营业收入2.3亿元,同比变动-7.4%,归母净利润为99
Graphic pre-biology three-quarter report: net profit per quarter in the third quarter decreased by 27.10% compared with the same period last year.
According to the third quarterly report of pre-science biology 2021, the company's main income was 776 million yuan, up 28.37% from the same period last year; the net profit was 386 million yuan, up 20.69% from the same period last year; and deducting 376 million yuan from non-net profit, up 20.04% from the same period last year. In the third quarter of 2021, the company's main income in a single quarter was 231 million yuan, down 7.42% from the same period last year; the net profit in a single quarter was 99.7647 million yuan, down 27.1% from the same period last year The non-net profit in a single quarter was 97.9147 million yuan, down 26.21% from the same period last year; the debt ratio was 18.68%, and the investment income was 3.7665 million.
No Data